Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:52:18.801Z.
Calculation as of: 2026-10-06T15:52:18.801Z.
Quote observation: 2026-10-06T15:49:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f972cfcdde9e4531ce3198b66662ffcb9080d57c966754dbe52ec7edaf14096
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
NervGen Pharma Corp. Common stock
Market Cap
$148.77M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$149.87M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.64M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$152.69M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$153.89M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $148.77M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | N/A | 177.92 | 1258.54 | 1258.54 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $149.87M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.64M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $145.39M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $146.11M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $152.20M | N/A | 55.06 | 55.06 | 55.06 |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.69M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $153.89M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $155.61M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
